Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QMF149 vs Budesonide in Children With Asthma
NCT05562466Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2023
- Primary completion
- Feb 2028
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of atectura breezhaler in asthma (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough Forced Expiratory Volume in 1 second at 12 weeks. Started May 2023; status: recruiting.
02
Drugs
atectura breezhaler
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05562466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562466.